Jump to content

Monalizumab

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by InternetArchiveBot (talk | contribs) at 07:21, 7 April 2020 (Rescuing 1 sources and tagging 0 as dead.) #IABot (v2.0). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Monalizumab
Monoclonal antibody
Type?
SourceHumanized
TargetNKG2A
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII

Monalizumab (formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies[1] and other cancers.[2][3]

Mechanism of action

Monalizumab is a monoclonal antibody targeted at NKG2A.[4] It is a checkpoint inhibitor.[5]

References

  1. ^ A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
  2. ^ IPH2201 studies
  3. ^ First Clinical Data For Monalizumab As A Single Agent In Cancer Patients Show Favorable Safety Profile
  4. ^ AstraZeneca Inks $1.8B in Immuno-Oncology Deals as Q1 Profit Dips
  5. ^ "monalizumab". Archived from the original on 2016-12-20. Retrieved 2016-12-09.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Monalizumab&oldid=949568183"